FDA Gives Herbal Healer Academy Lesson On CBD, GMPs, Labels, Homeopathics
Executive Summary
Warning is second FDA submitted in September referencing CBD as unlawful for use in supplements without also identifying non-compliant claims. It
You may also be interested in...
DMHA Gets FDA Attention At Alternative Labs, CBD Noticed While There
Warning doesn't reference any noncompliant claims for CBD-labeled Green Roads, but FDA explains the basis for which it has stated for two years it could warn every firm marketing products that are labeled as or found containing CBD.
Senate FDA Appropriation Includes $2M For CBD Enforcement Discretion Policy
Instruction in Appropriations Committee report on FY 2020 spending bill garners support from some stakeholders while others say setting a safe level of CBD's use in non-drug products should come first. Senate appropriators endorses FDA policy that regulations allowing sales of CBD non-drug products "not discourage the development of new drugs."
Safe Level For CBD As Dietary Ingredient? FDA Continues Data Review
Associate commissioner Lowell Schiller's comments at recent trade group regulatory conference mark agency's first public statement on likely direction on CBD's use in food, supplements. Potentially allowing CBD's use also is making FDA "think about whether we have the tools and resources we need to take this on," Schiller said.